No Data
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stifel Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $36
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Alnylam Pharma (ALNY) and Nurix Therapeutics (NRIX)
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Nurix Therapeutics Price Target Raised to $17.00/Share From $16.00 by Morgan Stanley
SniperInWood : Already 500% current year where is yearly bottom of strong buy potential
SniperInWood : Time to make separate watchlist of strong buys so get better cost price for less red days